>> teva's got this moos ache of companies that have bought and it's taking the pressure off the cope axezone, and generic threat and i think that teva which i have disliked intensely has bottomed and is beginning to creep up. we have a little discord in the market's concerto. they're still fine. you have to take the good with the bed and take the headphones on. enjoy the concert. "mad money" will be right back. >> coming up, dazed and confused. a few companies could be making investors sick by guiding them in circles. cramer thinks the cure might just be to sell them. >> sell, sell, sell. >> are they limping in your portfolio? stay tuned to find out. and later, full of energy. energy powerhouse devon beat analyst expectations this morning as they move away from that gas and find split profits in oil, but do they also just find a new source of the black gold. cramer's drilling for answers in its earnings exclusive with the company's ceo. plus ride the high seas? while the price you pay for gas at the pump may be rising, this company says the cost of transport oil by sea is bottoming.

we'll be talking to teva pharmaceuticals ceo william mart. back in two. intuitive trading platform that thinks like a trader. fine-tune technical analysis with the integrated chart tools sidebar. to seize an opportunity, i have to see it. with this, there's no more hide and seek. pinpoint your target more efficiently with clearly categorized, highly customizable technical studies. i'm looking for two things-where to get in, where to get out, so i find the study i want and make it look exactly how i want. plus, scan any stock or etf against time-tested indicators with built-in chart pattern recognition. you've gotta go beyond gut and get to the data. now i can see if a stock might go where i think it will go. customized charts. intuitive control. get started with streetsmart edge and get it all for the schwab price of $8.95 per trade. call 1-888-800-8026. open an account and trade up to 6 months commission-free. talk to chuck and get started with streetsmart edge today. ♪ >>> we are live from the financial capital of the world. the opening bel

this company makes ugg boots and teva sandals.sales were strong last quarter but it warned of big cost challenges this year and issued a disappointing outlook. meantime, crocs fell 5% also blamed on a down-beat forecast. while we're talking fashion, clothing designer kenneth cole shares jumped 18.5%. m the company's name-sake wants to take full ownership offering $15 per share to go private. the market expects a higher price, considering tonight's close is almost 50 cents above his offer. speaking of potential deals, late today, reports surfaced sprint nextel has walked away from a purchase of metro p.c.s., just hours away from announcing a deal. metro p.c.s. concentrates on pre-paid wireless customers. metro p.c.s. stock was 2.5% higher during the regular session and jumped another 8% after the close. sprint slid a nickel today, but it was very actively traded. and that's tonight's market focus. >> susie: jc penney's swung deep into the red with quarter results, but the stock barely budged. the retailer is promising to reshape it

listen, i have apple, chevron, kimberly clark, wynn, and teva, and i was wondering if i am diversifiedr that. >> let's go to work. chevron, major oil company, real good. apple, one of our favorite companies. wynn, i like the fact that they bought out the dissident casino, and kimberly, great yielding and teva, the ceo on "squawk on the street." drug, oil, tech, entertainment, and consumer products. that is perfect diversification, which by the way, a very nice yield when it comes to kimberly and to chevron. let's go to leon in pennsylvania. >> caller: hey, jim, a big booyah from southwestern pennsylvania. transplanted long islander here. long-time fan of yours, too. >> big marcellus shale booyah to you. >> caller: absolutely. i want to know if i'm diversified. i have apple, exxonmobil, united health group, mcdonald's, and proctor & gamble. >> let's get right to work. united health. large medical provider, doing very well by the way. missed that move, my bad. exxonmobil, largest oil company, not my favorite oil, but that's okay. no one ever got hurt owning exxon. computer company apple,

. >> reporter: engineers here at teva are used to making high performance shoes for humans, but taking the technology in something like this and shrinking it down to a perfect fit for a penguin brought a new set of challenges. >> we had to make sure he could get up and down the rocks with traction on uneven surfaces. >> reporter: it took some trial and error but when his feet were finally happy. >> when the right boot got there, it was glory, hallelujah, because he just stepped up, put his chest out. >> the best part was he could get in the water and swim. really improved his quality of life. >> reporter: oh, how his life has changed. lucky has his own song on youtube. ♪ penguin wearing a funky shoe >> reporter: and the bird who was different, now joins in all the penguin games. his new friends don't seem to notice his fancy footwear, his new winter booty, much more than a fashion statement. >> it really took a community to make this happen, and, you know, it saved his life. >> reporter: santa barbara's special little penguin, who seems to know just how lucky he is. kristen dahlgren, n

nobody is buying -- >> what are the profit margins bigger on uggs or tevas? >> probably the same.ou're talking about a piece of rubber with plastic on the one versus that suede boot on the other. >> sun power had good numbers today. surprisingly they had a profit instead of a loss. that was a big shocker. first solar made that big move because they have that deal with exelon for one of the larger solar farms in california. that was the momentum behind those two. it might be a buy rumor, sell situation. >> herb, forgive us for interrupting you. we apologize. >> i was just trying to do some other stuff. here's the deal. salesforce.com. next week this is probably going to be one of the most significant earnings for what i like to call battleground stocks. there's been a lot of chatter lately from analysts about big contracts the company appears to have gotten at the end of the year. an analyst at bernstein has a sell on sales force actually put out a report yesterday that sort of got lost in the shuffle here. it shouldn't. he used to work in the industry. what he says, he checked wit

the biggest opportunity in history was, of course, last november, when watson, teva launched their generic version of lipitor. now, the question is, though, which drugs present the next lucrative opportunity for these highly competitive generic companies. the top of the list is bristol-myers blood thinner plavix, which is a $1.6 billion. 90% of market share is lost in the first three months to the generic player. we understand that two international drugmakers are working on a generic version of plavix. another source of revenue, after the patent expirations, we spoke to a health care expert and investor. here's what he had to say. >> the big opportunity is that over the next ten years, over $100 billion of brand biotech drugs will go generic. >> so what are these by oh logics? they're the highly complex molecules derived from living cells. they see this as the next big opportunity, and a couple already getting a head start with approvals in europe, of biosimilars. and by 2020, biologics is $120 billion in annual sales will have lost patent protection. that's when the generic drugmakers ar